Ginkgo Bioworks Holdings, Inc.
DNANYSEHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M |
| Operating income | −$315.3M | −$559.8M | −$864.4M | −$2.21B | −$1.83B | −$137.0M |
| Net income | −$312.8M | −$547.0M | −$892.9M | −$2.10B | −$1.83B | −$126.6M |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675.2M |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M | $205.1M |
| Equity | $508.6M | $716.1M | $1.10B | $1.74B | $1.51B | $461.4M |
| EPS (diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 | $-0.10 |
| Shares out. | 58.2M | 54.4M | 50.0M | 1.89B | 1.61B | 1.29B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −185.3%
- Net margin
- −183.8%
- Return on equity
- −61.5%
- Return on assets
- −27.9%
- Return on capital (ROCE)
- −30.8%
- Liabilities / assets
- 54.6%
- Debt / equity
- 1.20×
- Book value / share
- $8.74
- Revenue growth (YoY)
- −25.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -16.72distress
- Accruals / assets
- −12.7%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Viking Global Investors LpPassive (13G)May 15, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Baillie Gifford & CoPassive (13G)Feb 5, 2026
- Cascade Investment, L.L.C.Passive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Che AustinPassive (13G)Feb 14, 2025
- Shetty Reshma P.Activist (13D)Feb 14, 2025
- Ark Investment Management LlcPassive (13G)Jan 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Canton Barry10% owner | Apr 7, 2026 | Option exercise | 27,738 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.5M | 2.7 | -13.5% |
| Apr 30, 2026 | 5.2M | 5.0 | -14.2% |
| Apr 15, 2026 | 6.1M | 5.8 | -0.8% |
| Mar 31, 2026 | 6.1M | 5.2 | -23.2% |
| Mar 13, 2026 | 8.0M | 5.8 | +6.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Completed an acquisition or dispositionApr 7, 2026
- Entered a material agreementFeb 27, 2026
- Results of operationsFeb 26, 2026
- Director / officer change · Other material eventDec 23, 2025
- Results of operationsNov 6, 2025
- Entered a material agreementSep 4, 2025
- Other material eventAug 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.